Introduction
Pain either alone or associated with other conditions is one of the main reasons for consultations in general practice [1] . Pain represents a global health problem with estimated about 20% adults suffering from pain [2] . Musculoskeletal conditions, one of the causes of pain are also a significant health problem worldwide. Patients of all age with acute musculoskeletal pain are frequently seen in clinical practice which needs to be successfully treated to avoid progression into chronic conditions [3] . Different analgesic agents from opioid and non-opioid group are available for the treatment of pain. Tramadol hydrochloride is a centrally acting analgesic which acts as a weak atypical opioid agonist and monoamine neurotransmitter reuptake inhibitor [4, 5] . Thus, the analgesia provided by tramadol is a result of both opioid and nonopioid mechanisms [6] which appear to act synergistically [7] . Paracetamol is rapidly acting non-opioid analgesic [8] routinely used in clinical practice. It is effective for the treatment of moderate pain [9] . Single analgesic agent can not treat all types of pain [10] , hence the analgesics are often selected based on the difference in pain severity and duration of pain [1] . Combination of analgesic agents with complementary mechanisms may provide higher efficacy because of the action on multiple pain-inhibiting pathways [10] and a better safety compared to individual agents [10, 11] . Fixed Dose oral Combination (FDC) of tramadol 37.5 mg plus paracetamol 325 mg is indicated for the symptomatic treatment of moderate to severe pain [5] . The combination has been shown to provide supra-additive analgesic effects [12] and well studied in acute moderate to severe pain.
Non-Steroidal Anti-Inflammatory agent (NSAID) can also be combined with an opioid for the management of moderate to severe acute pain because of their different mechanisms of action [13] . Similar to paracetamol [9] , NSAIDs also have opioid sparing action [14] . Diclofenac is a well studied and commonly used NSAID having analgesic, anti-inflammatory, and antipyretic properties. Multiple mechanisms of action including inhibition of thromboxane-prostanoid receptor, arachidonic acid release and uptake, lipoxygenase enzymes, and activation of the nitric oxide-cGMP antinociceptive pathway by diclofenac suggests better profile compared to other NSAIDs [15] . A fixed dose combination of immediate release tramadol plus sustained release diclofenac has been developed with the rationale of providing better analgesia in moderate to severe pain due to different and complimentary mechanisms of action and also to provide immediate as well as sustained pain relief.
The objective of this study was to evaluate the efficacy and safety of tramadol -diclofenac versus tramadol-paracetamol FDC in Indian patients with acute musculoskeletal pain.
Methods
A randomized, open label, comparative, parallel group, multi-centre trial was conducted to evaluate the efficacy and safety of the immediate release tramadol 50 mg plus sustained release diclofenac 75 mg FDC vs tramadol 37.5 mg plus paracetamol 325 mg FDC in treatment of patients with moderate to severe pain due to Acute Musculoskeletal Pain (AMSP), acute flare of osteoarthritis, acute flare of rheumatoid arthritis, or postoperative pain in Indian patients. The results of this study are published in 2014 [13] . In this paper, the subgroup analysis of comparative efficacy and safety of the two combinations in acute musculoskeletal conditions is presented. Adult subjects >18 years and < 70 years with clinical diagnosis of acute musculoskeletal pain (tendonitis, bursitis, synovitis) having VAS [16] score> 50 mm during last five days prior to the baseline visit were enrolled. Pregnant women, nursing mothers and those hypersensitive to tramadol, diclofenac or paracetamol were excluded. Patients with active peptic ulcer, gastrointestinal bleeding, having history of peptic ulcers, gastric irritations and NSAID intolerance, abnormal renal and liver functions and on any other treatment medications such as NSAIDs, corticosteroids, and opioid analgesics or alternate therapy (physiotherapy and acupuncture) were excluded from the study. During the treatment period, unbearable pain was treated with rescue medication diclofenac.
The enrolled subjects were treated with immediaterelease tramadol hydrochloride 50 mg plus sustained-release diclofenac sodium 75 mg one FDC tablet, twice daily or tramadol hydrochloride 37.5 mg and paracetamol 325 mg two FDC tablets every 4-6 hours, up to a maximum of eight tablets daily. The duration of treatment was five days. Randomization was done based on a PC based program Rando Version 2.0 ®.
The patients were assessed at baseline, on day 3 and day 5 of treat ment, on the following parameters: pain intensity, swelling, inflammation, and use of rescue medications. The primary efficacy parameter was reduction in pain intensity from baseline to day three and day five. The pain intensity was measured with a 0-100 mm VAS scale (for overall pain, pain at rest, and pain on movement). Pain relief was measured at the end of five day treatment. The global assessment of efficacy and tolerability was done at the end of study while laboratory investigations were performed at screening, baseline and day five.
Adverse events reported during the study period, abnormalities during physical examination, vital signs and laboratory analysis (haematological and biochemistry) were considered for safety analysis. Tolerability was assessed on a three point scale (good-side effects mild or not observed; moderate-side effects of moderate intensity; poor-severe side effects or discontinuation) and efficacy on a five point scale (poor, satisfactory, good, very good and excellent) at the end of the therapy.
The study protocol and informed consent form were approved by respective hospital's ethics committee. The study was conducted in accordance with the Declaration of Helsinki (1964). The patients reviewed and voluntarily signed the informed consent form before enrolment in the study.
Statistical analysis
Two treatment groups were evaluated for comparing demographic data and baseline symptom scores. Efficacy analysis was done with per-protocol population while safety analysis was done with intent-to-treat population. Quantitative data was analyzed using student's 't' test &analysis of variance (ANOVA), and ranking/qualitative data was analyzed using Mann-Whitney 'U' test and the Kruskall-Wallis test. Proportions were compared using the Chi-square test. P values <0.05 were considered statistically significant.
Results
A total of 52 patients were enrolled out of whom 51 completed the study. One patient from tramadol-paracetamol group lost to follow up. The baseline demographics are presented in table 1. No significant difference was seen in the gender between two groups. Other baseline parameters i.e. pulse rate, systolic and diastolic blood pressure were also comparable in both groups (table 1).
The reduction in the intensity of overall pain was assessed using VAS scale of 0-100 mm. The scores were compared between two groups. No significant difference in the mean or percentage change in the VAS score was observed between two groups at day 3 (table 2 and figure 1; p=0.233). However the difference in mean and percentage change in the VAS score was significant at day five (table 2 and figure 1; p=0.002) favouring tramadoldiclofenac over tramadol-paracetamol combination.
The mean and percentage change in the VAS score for pain at rest was not significantly different between two groups at day three (table 2 and figure 2; p=0.11). At day five, combination of tramadol-diclofenac resulted in significant improvement compared to tramadol-paracetamol combination (table 2 and figure 2; p<0.0001).
Similarly, for pain on movement, the mean or percentage difference in VAS score was not significant between two groups at day three (table 2 and figure 3; p=0.388). At day five, tramadoldiclofenac combination was significantly better in reducing mean and percentage VAS score compared to tramadol-paracetamol combination (table 2 and figure 3; p=0.003).
The mean and percentage reduction of swelling was significantly superior with tramadol -diclofenac compared to tramadol-paracetamol both at day three and five (table 2; day three p=0.002; day 5 p=0.012) while improvement in the mean score of inflammation was significantly better with tramadoldiclofenac combination at day 5 (table 2; p=0.001). The improvement in the total score of inflammation was significantly superior to tramadol-paracetamol combination at both visits (table 2; day three p=0.004; day five p < 0.0001).
Overall, a total of 15.38% and 32% patients receiving tramadol-diclofenac and tramadol-paracetamol respectively received concomitant medication. One day three and five there was no difference for use of concomitant medication between two groups.
Global assessment of efficacy data evaluated by both physician and patient is shown in table 3. The results showed that according to the global assessment of efficacy as evaluated by physician 88% patients receiving tramadol-diclofenac had very good to excellent efficacy while only 24% patients in the tramadol-paracetamol had very good to excellent efficacy ( table 3; p<0.0001). About 96% of patients who received tramadoldiclofenac had very good to excellent efficacy while 20% who received tramadol-paracetamol had very good to excellent efficacy ( table 3; p<0.0001). Table 4 shows the global assessment of tolerability evaluated by physicians and patients. According to the global assessment of tolerability evaluated by physician 88.46% patients who 
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received tramadol-diclofenac had good tolerability while 88% patients in the tramadol-paracetamol group had moderate to good tolerability ( table 3; p<0.0001). The global assessment of tolerability as evaluated by patients was good in 92.31% and 24% patients who received tramadol-diclofenac and tramadolparacetamol respectively ( table 3; p<0.0001).
The overall incidence of adverse events was 11.54% and 24% with tramadol-diclofenac and tramadol-paracetamol respectively. The rate of adverse events was less in tramadol-diclofenac group on both days (day 3: 7.69% vs 20%; day 5: 11.54% vs 16%; table 5)). All the adverse events were gastrointestinal (gastritis, nausea and vomiting) in nature except drowsiness reported by one patient receiving tramadol-paracetamol on day three. No serious adverse event was reported in this study.
Discussion
The combination of diclofenac and tramadol provides advantage of different mechanisms of action with potential for wider spectrum of pain relief. Our group has recently published 
Day 3
Nausea, n (%) 1 (3.85) 2 (8%)
Day 5
Nausea, n (%) 2 (7.69) 2 (8%)
Gastritis, n (%) 1 (3.85) 1 (4%) a phase three Indian study which demonstrated that tramadoldiclofenac FDC results in significantly greater analgesia compared to tramadol-paracetamol in patients with moderate to severe pain due to acute musculoskeletal conditions, postoperative pain following orthopaedic surgery, or acute flare of osteoarthritis and rheumatoid arthritis [13] . In this paper, we com pared the safety and efficacy of tramadol-diclofenac with tramadol-paracetamol, as an analgesic agent in subgroup population of moderate to severe pain in acute musculoskeletal conditions. The results of this subgroup analysis confirm that tramadol and diclofenac is the rational combination for management of moderate to severe pain in acute musculoskeletal conditions.
In acute musculoskeletal pain, tramadol-diclofenac administration resulted in greater reduction of swelling and total score of inflammation compared to tramadol-paracetamol both at day three and five. Diclofenac is a non-steroidal antiinflammatory agent [16] . The anti-inflammatory property of diclofenac provides an advantage in acute inflammatory musculoskeletal pain as paracetamol does not have any effect on the inflammatory mediators [17] .
The VAS score for overall pain was significantly reduced after combination therapy of tra madol and diclofenac. Mitra et al [18] have showed that diclofenac-tramadol and diclofenacparacetamol combinations are effective in providing postoperative pain control after caesarean section. The investigators demonstrated that the overall efficacy of diclofenac-tramadol combination is better than diclofenac-paracetamol.
Similarly, another comparative study has evaluated the efficacy and safety of diclofenac-tramadol [19] . Compared to diclofenac alone, the combination has been shown to provide faster and longer pain relief in patients after unilateral hallux valgus surgery. The combination was found to be well tolerated in acute inflammatory pain of moderate to severe intensity [19] .
We did not find any comparative study of tramadol-diclofenac combination in acute musculoskeletal pain. In this regards, our study results provide unique insights about efficacy and safety of combination in subset of population with moderate to severe pain.
Both the combinations were well tolerated by patient population in our study. The incidence of adverse events was less in patients receiving the tramadol-diclofenac combination compared with those receiving the tramadol-paracetamol combination, on both day 3 and day 5. The difference in rate of adverse events can partly be explained by higher number of patients receiving concomitant medication in tramadolparacetamol group. The dose of tramadol in FDC with diclofenac sodium was 100 mg per day versus 150-225 (up to maximum of 300 mg) mg per day in FDC with paracetamol. Higher dose of tramadol with paracetamol combination could be another possibility for more adverse events.
In the study conducted by Mitra et al [18] , tramadol-diclofenac was associated with comparable side effects with tramadolparacetamol and higher incidence of post-operative nausea. Use of rescue analgesic intake was similar between two groups (P = 0.872). In our study also, the use of concomitant medication was similar on day three and five.
The difference was in the route of administration. In this study tramadol was used as oral medication while Mitra et al [18] used intravenous tramadol.
All the adverse events in our study were mild to moderate in nature, with self-limiting gastrointestinal adverse events (gastristis, nausea and vomiting) being most common.
This study has some limitations. Small sample size limits the extrapolation of the results to entire population with acute musculoskeletal pain. The results of this paper are limited only to patients with acute musculoskeletal pain. A separate subgroup analysis needs to be conducted to see whether similar trend of results were seen in acute flare of osteoarthritis, acute flare of rheumatoid arthritis and postoperative pain. The study was conducted in controlled setting to evaluate the role of co morbidities in these patients; a study in real-world settings is required. Lastly, though the study was conducted in controlled setting with randomization, an open label study design leaves an area for suspecting bias.
Conclusion
The tramadol-diclofenac combination resulted in significantly greater reduction in VAS scores for overall pain, pain at rest and pain on movement on day five compared to tramadol-paracetamol combination. Mean score for swelling and total score for inflammation, was significantly better with tramadol-diclofenac combination compared with the tramadolparacetamol combination both at day three and five. Both the formulations caused mainly GI side effects of mild to moderate intensity without any serious adverse event warranting discontinuation of treatment.
